Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center | Zendy

Sudha Murthy | Zendy; DG Sandhya | Zendy; Faiq Ahmed | Zendy; KIravathy Goud | Zendy; Monal Dayal | Zendy; Kundoly Velayudhan Suseela | Zendy; Senthil J. Rajappa | Zendy

Open Access

Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center

Author(s) -

Sudha Murthy,

DG Sandhya,

Faiq Ahmed,

KIravathy Goud,

Monal Dayal,

Kundoly Velayudhan Suseela,

Senthil J. Rajappa

Publication year - 2011

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 31

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/0377-4929.85087

Subject(s) - polysomy , immunohistochemistry , fluorescence in situ hybridization , breast cancer , concordance , trastuzumab , medicine , oncology , pathology , cancer , ductal carcinoma , gene duplication , biology , gene , chromosome , genetics

HER-2/neu status determines the eligibility for targeted therapy with trastuzumab in breast carcinoma. Evaluation for HER-2/neu protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) has become the gold standard.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research